170291-52-8

Usage

| Molecular weight

| 389.47 g/mol |

| Chemical structure

| 1-Piperidinecarboxylic acid, 4-(4-fluorophenyl)-4-(hydroxymethyl)-, 1,1-dimethylethyl ester |

| Synonyms

| Tadalafil |

| Medicinal use

| Treatment of erectile dysfunction and benign prostatic hyperplasia |

| Mechanism of action

| Phosphodiesterase 5 (PDE5) inhibitor, relaxes muscles, and increases blood flow to certain areas of the body |

| Administration

| Taken as needed, about 30 minutes before sexual activity |

| Duration

| Can last in the system for up to 36 hours |

| Side effects

| May include headache, stomach upset, muscle pain, and back pain |

| Precautions

| Consult with a healthcare professional before use to ensure it is safe and appropriate |

Upstream product

• 1368648-25-2 C₁₂H₁₆FNO 
• 24424-99-5 di-tert-butyl dicarbonate 
• 1429661-32-4 C₁₉H₂₆FNO₄ 
• 627-11-2 2-Chloroethyl chloroformate 
• 643756-79-0 C₁₇H₂₂FNO₃ 
• 644981-89-5 1-(tert-butoxycarbonyl)-4-(4-fluorophenyl)piperidine-4-carboxylic acid 

Downstream Products

• 954124-01-7 tert-butyl 4-((3-bromo-5-(trifluoromethyl)benzyloxy)methyl)-4-(4-fluorophenyl)piperidine-1-carboxylate 
• 672926-84-0 1-N-t-BOC-4-(4-fluorophenyl)-4-[(3-cyano-2,4-dimethoxynaphth-1-yl)methoxymethyl]piperidine 
• 1004794-09-5 tert-butyl 4-(((6-chloro-4-(trifluoromethyl)pyridine-2-yl)methoxy)methyl)-4-(4-fluorophenyl)piperidine-1-carboxylate 
• 160376-79-4 (4-(4-fluorophenyl)-1-methylpiperidin-4-yl)methanol 
• 1421961-56-9 4-(((6-cyclopropyl-4-(trifluoromethyl)pyridine-2-yl)methoxy)methyl)-4-(4-fluorophenyl)-1-methylpiperidin-1-ium chloride 
• 1100218-34-5 tert-butyl 4-((1-(1-ethyl-6-(trifluoromethyl)-1H-benzo[d]imidazol-4-yl)ethoxy)methyl)-4-(4-fluorophenyl)piperidine-1-carboxylate 
• 1100218-32-3 tert-butyl 4-((1-(1-(cyclopropylmethyl)-6-(trifluoromethyl)-1H-benzo[d]imidazol-4-yl)ethoxy)methyl)-4-(4-fluorophenyl)piperidine-1-carboxylate 
• 1100216-08-7 tert-butyl 4-((1-(5-chloro-2-((2-(trimethylsilyl)ethoxy)methyl)-2H-indazol-7-yl)-2-methoxy-2-oxoethoxy)methyl)-4-(4-fluorophenyl)piperidine-1-carboxylate 
• 1100215-74-4 tert-butyl 4-(4-fluorophenyl)-4-(((6-(trifluoromethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d][1,2,3]triazol-4-yl)methoxy)methyl)piperidine-1-carboxylate 
• 1100215-45-9 tert-butyl 4-(4-fluorophenyl)-4-((((5-(trifluoromethyl)-1-((2-trimethylsilyl)ethoxy)methyl)-1H-indol-7-yl)methoxy)methyl)piperidine-1-carboxylate 
• 1100215-14-2 (+/-)-tert-Butyl 4-((1-(5-chloro-2-cyclopropyl-2H-indazol-7-yl)ethoxy)methyl)-4-(4-fluorophenyl)piperidine-1-carboxylate 
• 1100214-91-2 (+/-)-tert-butyl 4-((1-(3-bromo-5-chloro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazol-7-yl)ethoxy)methyl)-4-(4-fluorophenyl)piperidine-1-carboxylate 
• 1100214-52-5 (+/-)-tert-butyl 4-((1-(5-fluoro-2-((2-(trimethylsilyl)ethoxy)methyl)-2H-indazol-7-yl)ethoxy)methyl)-4-(4-fluorophenyl)piperidine-1-carboxylate 
• 1100214-23-0 (+/-)-tert-butyl 4-(4-fluorophenyl)-4-((1-(5-methoxy-2-((2-(trimethylsilyl)ethoxy)methyl)-2H-indazol-7-yl)ethoxy)methyl)piperidine-1-carboxylate 

Relevant academic research and scientific papers

Development of a scalable route to a dual NK-1/serotonin receptor antagonist

The evolution of a process for the preparation of a new heterocyclic dual NK1/serotonin receptor antagonist is described. The final synthesis features a telescoped sequence in which an iron(III)-catalyzed Grignard coupling is followed by a benzylic chlori

Substituted Heterocyclic Ethers and Their Use in CNS Disorders

The invention encompasses compounds of Formula I, including pharmaceutically acceptable salts, their pharmaceutical compositions, and their use in treating CNS disorders.

SUBSTITUTED HETEROCYCLIC ETHERS AND THEIR USE IN CNS DISORDERS

The invention encompasses compounds of Formula I, including pharmaceutically acceptable salts, their pharmaceutical compositions, and their use in treating CNS disorders.

SUBSTITUTED HETEROCYCLIC ETHERS AND THEIR USE IN CNS DISORDERS

The invention encompasses compounds of Formula I, including pharmaceutically acceptable salts, their pharmaceutical compositions, and their use in treating CNS disorders.

NK-1 AND SEROTONIN TRANSPORTER INHIBITORS

The invention encompasses compounds of Formula I, including pharmaceutically acceptable salts, their pharmaceutical compositions, and their use in treating disorders associated with an excess or imbalance of tachykinins or serotonin or both.

1-AMIDO-4-PHENYL-4-BENZYLOXYMETHYL-PIPERIDINE DERIVATIVES AND RELATED COMPOUNDS AS NEUROKININ-1(NK-1) ANTAGONISTS FOR THE TREATMENT OF EMESIS, DEPRESSION, ANXIETY AND COUGH

Disclosed are NK1 antagonists having the formula: Also disclosed are uses of compounds of formula (I) for the manufacture of a medicament for treating a number of physiological disorders, symptoms or diseases, including emesis, depression, anxiety and cough.

NAPHTHYL ETHER COMPOUNDS AND THEIR USE

Compounds having the following structure wherein R1, R2, R3, R4, R5, R6, R7 m and n are as defined in the specification, in vivo-hydrolysable precursors thereof, pharmaceutically-acceptable salts thereof, the use in therapy and pharmaceutical compositions and methods of treatment using the same.

Gem-disubstituted azacyclic tachykinin antagonists

The present invention is directed to certain compounds represented by structural formula I: STR1 or a pharmaceutically acceptable salt thereof wherein R 1, R 2, R 3, R 4, R 5, R 6, R 7, A 1, A 2, X, m and n are defined herein. The compounds of this invention are tachykinin receptor antagonists and are of particular use in the treatment of pain, inflammation, migraine and emesis.